Drug profile · INN
vemurafenib
ZELBORAF
vemurafenib (ZELBORAF) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Drug details — vemurafenib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 8
- Data quality
- 0.84
Quick answer
vemurafenib (ZELBORAF) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serine/threonine-protein kinase B-raf inhibitor
Primary target: Serine/threonine-protein kinase B-raf
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is vemurafenib?
vemurafenib (ZELBORAF) is a serine/threonine-protein kinase b-raf inhibitor. Associated with Hoffmann-La Roche. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vemurafenib?
ZELBORAF is a marketed brand name for vemurafenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vemurafenib?
vemurafenib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.